TVARDI THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
TVARDI THERAPEUTICS, INC. (TVRD) reported Payments to Acquire Debt Securities, Available-for-sale of $32.21 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2024-03-31 was $32.21M, a 103.98% increase year-over-year.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $32.21M, a 71.64% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $113.61M, a 18.73% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $95.69M, a 54.17% decline from fiscal 2021.
- TVARDI THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $208.79M, a 10.34% decline from fiscal 2020.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $32.21M 10-K · filed 2025-03-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $32.21M 10-Q · filed 2024-11-14 | $97.22M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $32.21M 10-Q · filed 2024-08-14 | $97.22M derived: sum of 3 quarters · filed 2025-05-13 | $120.06M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $32.21M 10-Q · filed 2025-05-13 | $97.22M derived: sum of 2 quarters · filed 2025-05-13 | $120.06M derived: sum of 3 quarters · filed 2025-05-13 | $130.03M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $65.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $87.85M derived: sum of 2 quarters · filed 2025-03-11 | $97.81M derived: sum of 3 quarters · filed 2025-03-11 | $113.61M 10-K · filed 2025-03-11 |
| 2023-09-30 | $22.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $32.81M derived: sum of 2 quarters · filed 2024-11-14 | $48.60M 10-Q · filed 2024-11-14 | $66.43M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $9.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $25.75M 10-Q · filed 2024-08-14 | $43.58M derived: sum of 3 quarters · filed 2025-03-11 | $90.34M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $15.79M 10-Q · filed 2024-05-13 | $33.62M derived: sum of 2 quarters · filed 2025-03-11 | $80.38M derived: sum of 3 quarters · filed 2025-03-11 | $100.95M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $17.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $64.59M derived: sum of 2 quarters · filed 2025-03-11 | $85.16M derived: sum of 3 quarters · filed 2025-03-11 | $95.69M 10-K · filed 2025-03-11 |
| 2022-09-30 | $46.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $67.33M derived: sum of 2 quarters · filed 2023-11-13 | $77.86M 10-Q · filed 2023-11-13 | $177.66M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $20.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $31.10M 10-Q · filed 2023-08-07 | $130.91M derived: sum of 3 quarters · filed 2024-03-06 | $176.12M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $10.53M 10-Q · filed 2023-05-15 | $110.33M derived: sum of 2 quarters · filed 2024-03-06 | $155.55M derived: sum of 3 quarters · filed 2024-03-06 | $195.34M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $99.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $145.02M derived: sum of 2 quarters · filed 2024-03-06 | $184.81M derived: sum of 3 quarters · filed 2024-03-06 | $208.79M 10-K · filed 2024-03-06 |
| 2021-09-30 | $45.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $85.00M derived: sum of 2 quarters · filed 2022-11-07 | $108.99M 10-Q · filed 2022-11-07 | $320.85M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $39.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $63.77M 10-Q · filed 2022-08-08 | $275.64M derived: sum of 3 quarters · filed 2023-03-06 | $275.64M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $23.98M 10-Q · filed 2022-05-09 | $235.85M derived: sum of 2 quarters · filed 2023-03-06 | $235.85M derived: sum of 3 quarters · filed 2023-03-06 | $235.85M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $211.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $211.87M derived: sum of 2 quarters · filed 2023-03-06 | $211.87M derived: sum of 3 quarters · filed 2023-03-06 | $232.88M 10-K · filed 2023-03-06 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $21.02M 10-Q · filed 2021-11-08 | $66.02M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $21.02M 10-Q · filed 2021-08-09 | $66.02M derived: sum of 3 quarters · filed 2022-03-01 | $235.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $21.02M 10-Q · filed 2021-05-10 | $66.02M derived: sum of 2 quarters · filed 2022-03-01 | $235.86M derived: sum of 3 quarters · filed 2022-03-01 | $254.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $45.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $214.85M derived: sum of 2 quarters · filed 2022-03-01 | $233.20M derived: sum of 3 quarters · filed 2022-03-01 | $286.08M 10-K · filed 2022-03-01 |
| 2019-09-30 | $169.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $188.19M derived: sum of 2 quarters · filed 2020-11-09 | $241.07M 10-Q · filed 2020-11-09 | $440.24M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $18.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $71.24M 10-Q · filed 2020-08-10 | $270.40M derived: sum of 3 quarters · filed 2021-02-25 | $310.82M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $52.88M 10-Q · filed 2020-05-11 | $252.05M derived: sum of 2 quarters · filed 2021-02-25 | $292.47M derived: sum of 3 quarters · filed 2021-02-25 | $373.94M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $199.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $239.58M derived: sum of 2 quarters · filed 2021-02-25 | $321.05M derived: sum of 3 quarters · filed 2021-02-25 | $337.85M 10-K · filed 2021-02-25 |
| 2018-09-30 | $40.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $121.89M derived: sum of 2 quarters · filed 2019-11-05 | $138.69M 10-Q · filed 2019-11-05 | $150.34M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $81.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $98.27M 10-Q · filed 2019-08-07 | $109.92M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | $16.80M 10-Q · filed 2019-05-07 | $28.45M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $127.39M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $115.75M 10-Q · filed 2018-11-06 | |||
| 2016-12-31 | $68.65M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |